A study protocol for a phase II randomised, double-blind, placebo-controlled trial of sodium selenate as a disease-modifying treatment for behavioural variant frontotemporal dementia

A study protocol for a phase II randomised, double-blind, placebo-controlled trial of sodium selenate as a disease-modifying treatment for behavioural variant frontotemporal dementia

Introduction Behavioural variant frontotemporal dementia (bvFTD) is a neurodegenerative disorder often neuropathologically associated with the accumulation of abnormally hyperphosphorylated tau, for which there is currently no disease-modifying treatment. Previous work by our group has shown sodium...

Full description

Saved in:
Bibliographic Details
Main Authors: Rebekah M Ahmed, Lucy Vivash, Dennis Velakoulis, Leonid Churilov, Olivier Piguet, David Darby, Terence J O'Brien, Charles B Malpas, Mark Walterfang, Amy Brodtmann, Ashley I Bush, Christopher M Hovens, T Kalincik
Format: Article
Language:English
Published: BMJ Publishing Group 2020-11-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/10/11/e040100.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://bmjopen.bmj.com/content/10/11/e040100.full

Similar Items